Tigermed(300347) 搜狐财经·2025-04-07 10:24Group 1 - The core viewpoint of the news is that Tiger Med's stock price has significantly declined, leading to a high rolling PE ratio compared to the industry average [1] - As of April 7, Tiger Med's closing price was 45.8 yuan, down 10.72%, with a rolling PE ratio of 97.78 times and a total market capitalization of 39.615 billion yuan [1] - The company experienced a net outflow of main funds amounting to 122.997 million yuan on April 7, with a total outflow of 187.169 million yuan over the past five days [1] Group 2 - Tiger Med is primarily engaged in providing comprehensive clinical research solutions as a Contract Research Organization (CRO) for new drug development [1] - The company's latest financial results for the year 2024 show a revenue of 6.603 billion yuan, a year-on-year decrease of 10.58%, and a net profit of 405 million yuan, down 79.99% [1] - The gross profit margin for the company stands at 33.95% [1] Group 3 - In terms of industry comparison, the average PE ratio for the medical services sector is 45.72 times, with a median of 41.83 times, placing Tiger Med at the 38th position in the industry ranking [2] - The industry average market capitalization is 142.68 billion yuan, while the median is 43.24 billion yuan [2]